Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.23.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2023
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Period Ended March 31, 

($ in thousands)

    

2023

    

2022

Qbrexza®

$

4,094

$

7,376

Accutane®

 

4,648

 

4,907

Amzeeq®

1,193

3,466

Targadox®

793

2,634

Ximino®

612

967

Exelderm®

 

511

 

704

Zilxi®

314

741

Other branded revenue

 

 

1

Total product revenues

$

12,165

$

20,796

Schedule of other revenue

    

Three-Month Period Ended March 31,

($ in thousands)

    

2023

    

2022

Other revenue

 

$

48

 

$

2,500

Total other revenue

$

48

$

2,500